Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Schwartz JA, Prado I, Misamore J, Weiss D, Francis J, Pal R, Huaman M, Cristillo A, Lewis GK, Gallo RC, DeVico AL, Fouts TR.

Clin Vaccine Immunol. 2016 Jul 5;23(7):618-27. doi: 10.1128/CVI.00115-16. Print 2016 Jul.

PMID:
27193040
2.

Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection.

Sheng Z, Schramm CA, Connors M, Morris L, Mascola JR, Kwong PD, Shapiro L.

PLoS Comput Biol. 2016 May 18;12(5):e1004940. doi: 10.1371/journal.pcbi.1004940. eCollection 2016 May.

3.

Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.

Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J, Shao Y.

Immunity. 2016 Apr 19;44(4):939-50. doi: 10.1016/j.immuni.2016.03.006. Epub 2016 Apr 5.

PMID:
27067056
4.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-45. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

PMID:
26984721
5.
6.

Broadly Neutralizing Antibodies for HIV Eradication.

Stephenson KE, Barouch DH.

Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7. doi: 10.1007/s11904-016-0299-7.

7.

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.

Bolton DL, Pegu A, Wang K, McGinnis K, Nason M, Foulds K, Letukas V, Schmidt SD, Chen X, Todd JP, Lifson JD, Rao S, Michael NL, Robb ML, Mascola JR, Koup RA.

J Virol. 2015 Nov 18;90(3):1321-32. doi: 10.1128/JVI.02454-15.

8.

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS; VRC 602 Study Team.

Clin Exp Immunol. 2015 Dec;182(3):289-301. doi: 10.1111/cei.12692. Epub 2015 Sep 24.

PMID:
26332605
9.

Strategies to guide the antibody affinity maturation process.

Doria-Rose NA, Joyce MG.

Curr Opin Virol. 2015 Apr;11:137-47. doi: 10.1016/j.coviro.2015.04.002. Epub 2015 Apr 24. Review.

10.

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.

Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, Sheng Z, Zhang B, O'Dell S, McKee K, Georgiev IS, Chuang GY, Longo NS, Lynch RM, Saunders KO, Soto C, Srivatsan S, Yang Y, Bailer RT, Louder MK; NISC Comparative Sequencing Program, Mullikin JC, Connors M, Kwong PD, Mascola JR, Shapiro L.

Cell. 2015 Apr 23;161(3):470-85. doi: 10.1016/j.cell.2015.03.004. Epub 2015 Apr 9.

11.

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.

Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, Ko SY, Chen X, Schmidt SD, Haase AT, Todd JP, Bao S, Kwong PD, Rao SS, Mascola JR, Nabel GJ.

J Virol. 2015 Jun;89(11):5895-903. doi: 10.1128/JVI.00210-15. Epub 2015 Mar 18.

12.

HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Acharya P, Lusvarghi S, Bewley CA, Kwong PD.

Expert Opin Ther Targets. 2015 Jun;19(6):765-83. doi: 10.1517/14728222.2015.1010513. Epub 2015 Feb 27. Review.

13.

Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.

Dey B, Berger EA.

Curr Opin HIV AIDS. 2015 May;10(3):207-13. doi: 10.1097/COH.0000000000000151. Review.

14.

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR.

J Virol. 2015 Apr;89(8):4201-13. doi: 10.1128/JVI.03608-14. Epub 2015 Jan 28.

15.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

16.

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL.

PLoS Pathog. 2013 Oct;9(10):e1003738. doi: 10.1371/journal.ppat.1003738. Epub 2013 Oct 31.

17.

Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Kwon YD, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC; NISC Comparative Sequencing Program, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Immunity. 2013 Aug 22;39(2):245-58. doi: 10.1016/j.immuni.2013.04.012. Epub 2013 Aug 1.

18.

Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.

Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L.

J Virol. 2013 May;87(9):4882-94. doi: 10.1128/JVI.03424-12. Epub 2013 Feb 13.

19.

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N.

Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.

20.

Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.

Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M, Kankasa C, Thea DM, Mullins JI, Kuhn L, Aldrovandi GM.

AIDS. 2013 Jan 28;27(3):337-46. doi: 10.1097/QAD.0b013e32835cadd6.

Items per page

Supplemental Content

Write to the Help Desk